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Purpose: The goal of this study was to evaluate the
concurrent control rate of hypertension and
dyslipidemia by fimasartan and rosuvastatin in
patients who were concomitantly prescribed both
drugs.
Methods: : This single-center, cross-sectional study
was conducted in 536 patients with hypertension and
dyslipidemia who were taking fimasartan and
rosuvastatin together for at least 12 weeks. Patients
were enrolled from October 2016 to March 2018 at
a tertiary hospital in the Republic of Korea. The
primary end point was the concurrent control rate of
blood pressure (<140/90 mm Hg) and LDL-C. As a
secondary end point, the target blood pressure <130/
80 mm Hg was adopted in all patients or in high-risk
patients with atherosclerotic cardiovascular diseases.
Target LDL-C and noneHDL-C levels followed the
domestic guidelines. Correlation between blood
pressure control and lipid profile was also evaluated.
All parameters were assessed in a clinic by board-
certified physicians.
Findings: Of the total 536 patients, 69% (n ¼ 368)
had very high (n ¼ 308) or high (n ¼ 60)
cardiovascular risk, with an average age of 65 years;
57% were male. When the target blood pressure was
set at 140/90 mm Hg, the proportion of patients
meeting the targeting LDL-C level was 40.3% (95%
CI, 36.2e44.5; P < 0.001). When applied to the
revised blood pressure criteria targeting 130/80 mm
Hg, the concurrent control rate dropped by one half1058to 20.3% (95% CI, 17.2e24.0; P < 0.001). To apply
the new blood pressure criteria, more intensive
management is mandatory in patients with high or
very high cardiovascular risk. There was no positive
correlation between the controlled rate of
hypertension and dyslipidemia.
Implications: Fimasartan and rosuvastatin were
shown to have effects on target diseases, but there
was no synergistic effect when administered in
combination. The higher the cardiovascular risk of
the patients, the lower the rate of concurrent control
when fimasartan and rosuvastatin were administered
simultaneously. More active treatment is therefore
required in high-risk patients. (Clin Ther.
2020;42:1058e1066) © 2020 The Authors. Pub-
lished by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Key words: angiotensin receptor blocker, fima-
sartan, hypertension, rosuvastatin.INTRODUCTION
Cardiovascular disease is the leading cause of death
worldwide, with 15.2 million deaths per year (as of(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Volume 42 Number 6
S.-J. Lee et al.2016), accounting for 27% of all deaths.1 According to
the Korean Heart Study (KHS), which has followed up
430,920 men and women in the Republic of Korea for
~15 years (1997e2011), cardiovascular disease has a
mortality rate of ~16%.2 Hypertension and
dyslipidemia are the biggest risk factors for
cardiovascular disease, and patients with
hypertension are more likely to have dyslipidemia
than normal blood pressure, and vice versa.3,4 This is
presumably because both diseases induce endothelial
damage, thereby accelerating the progress of
atherosclerosis.5 The ICEBERG (Intensive/Initial
Cardiovascular Examination regarding Blood
Pressure levels, Evaluation of Risk Groups) study,
which investigated the relation between dyslipidemia
and other cardiovascular risk factors in patients with
hypertension or stage 2 prehypertension, revealed the
positive correlation between blood pressure and
cholesterol level.6 Despite the importance of
managing hypertension and dyslipidemia, few data
exist on the concurrent control rate of these diseases.
A previous report that investigated 2864 adults aged
20 years (52% women) indicated that the
prevalence of both hypertension and dyslipidemia
was 18%, and the successful control of both
hypertension and dyslipidemia was achieved in only
9% of participants.7
The primary drug for dyslipidemia treatment is a
statin, a 3-hydroxy-3-methylglutaryl-coenzyme A
reductase inhibitor. Statins have long-term
therapeutic benefits in reducing cardiovascular events
and death, primarily by lowering cholesterol levels,
but there is also growing interest in the additional
effects of statins, such as lowering blood
pressure.8e10 Although the supporting evidence is
limited, a meta-analysis which included 20 studies
showed that in patients with systolic blood pressure
(SBP) levels >130 mm Hg, statins were shown to
reduced blood pressure ~4.0 mm Hg.11 A double-
blind, randomized controlled study also showed the
blood pressureelowering effect of statins (SBP,
2.2 mm Hg reduction [P ¼ 0.02]; diastolic blood
pressure, 2.4 mm Hg reduction [P < 0.001]).12
Indeed, combination treatment of an angiotensin II
receptor antagonist with a statin is very common in
clinical practice, and hence a combined formulation
of these drug classes is widely used.
Given the close correlation between hypertension
and dyslipidemia, as well as their targeting agents,June 2020the present study included patients who were taking
rosuvastatin for the treatment of dyslipidemia along
with fimasartan for the treatment of hypertension




Patients with hypertension being prescribed
fimasartan and rosuvastatin were screened and
enrolled in the outpatient clinic of a tertiary hospital
in the Republic of Korea from October 2016 to
March 2018. Patients were considered eligible for
enrollment if they met the following criteria: male or
female adults aged >20 years who signed an
informed consent form and had been treated with
antihypertensive medication containing fimasartan for
at least 12 weeks and had been treated with
antidyslipidemia medication containing rosuvastatin
for at least 12 weeks. Blood pressure and lipid
profiles of all patients enrolled in this study were
acquired. Patients were excluded from this study if
they were admitted at enrollment, had skipped
fimasartan or rosuvastatin >14 days within 12 weeks
before enrollment, had triglyceride levels >400 mg/
dL, were included in another clinical trial, or were
unsuitable for recruitment per the researcher’s
decision. Because FIMARO (Fimasartan and
Rosuvastatin for Hypertension and Dyslipidemia
Control) was a cross-sectional study, patients who
withdrew their signed consent were excluded from
the analysis.
Study Design
This was a single-center, noninterventional, cross-
sectional study. The study was ended by collecting
patients' clinical and laboratory parameters assessed
at the time of each participant’s enrollment.
However, some patients' history and medical records
were collected retrospectively. Fimasartan* is a non-
peptide angiotensin II receptor antagonist used for
the treatment of hypertension. It is marketed in the
Republic of Korea and currently registered in 18
different countries. The present study aimed to
evaluate a concurrent control rate of blood pressure
and cholesterol level in patients taking fimasartan
together with rosuvastatin. Patients with essential
hypertension and dyslipidemia who were
concurrently taking medications including fimasartan1059
Clinical Therapeuticsand rosuvastatin were enrolled after signing an
informed consent form. At the time of enrollment,
demographic information, hypertensive disease
characteristics, lipid profiles, and treatment
characteristics were examined. The demographic
information included sex, age, and body mass index.
Clinical characteristics included history of diabetes
mellitus, coronary artery disease, peripheral artery
disease, and cerebrovascular accident.
The study drug was administered according to
product labeling. The study doses of fimasartan
administered were 15, 30, 60, and 120 mg; most
patients were prescribed 30 or 60 mg. The study
doses of rosuvastatin administered were 5, 10, and
20 mg; doses of 40 mg were not available at our
institution. The primary end point was concurrent
control rate of blood pressure and LDL-C levels.
Target blood pressure was 140/90 mm Hg according
to the Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure.13
Blood pressure was measured twice from both arms
at initial registration, and the arm measuring the higher
SBP was used. When the SBPs of both arms were equal,
the arm with the higher diastolic blood pressure was
used. The mean value of 2 measurements was used.
As a secondary end point, we also adopted the newly
proposed 2018 American College of Cardiology/
American Heart Association (ACC/AHA)
hypertension guidelines suggesting a target blood
pressure <130/80 mm Hg14 and domestic guidelines
which suggest a target blood pressure <130/80 mm
Hg only in patients at high risk for atherosclerotic
cardiovascular diseases (ASCVDs).15 The target levels
for LDL-C and noneHDL-C followed the domestic
guidelines (see Supplemental Table I in the online
version at doi:10.1016/j.clinthera.2020.03.019).
Correlation between blood pressure control and lipid
profile was also evaluated *. The institutional review
board at Severance Cardiovascular Hospital was
responsible for approval of the clinical study, which
was conducted in accordance with ethical principles
and the Guidelines of the Declaration of Helsinki and
regulations and guidelines of Good Clinical Practice.* Trademark: Kanarb
®
(Boryung Pharmaceutical Co,
Ltd, Seoul, Republic of Korea).
1060Statistical Analysis
Treatment information regarding hypertension and
dyslipidemia were coded by using the Anatomical
Therapeutic Chemical classification system
developed by the World Health Organization, and
the total number and ratio were obtained.
Descriptive statistics for the mean, SD, median,
minimum, and maximum values are presented for
continuous variables. Frequencies and percentages
are presented for categorical variables. Continuous
variables that were normally distributed are
reported as mean (SD) and were compared by using
Student t tests for parametric data and
ManneWhitney tests for nonparametric data.
Categorical variables are reported as counts
(percentages) and were compared by using c2 or
Fisher exact tests. The significance level was 5%
(two-sided), and SAS version 9.4 (SAS Institute, Inc,
Cary, NC) was used for the analysis.RESULTS
Baseline Characteristics
A total of 536 patients who were concomitantly
prescribed fimasartan and rosuvastatin for the
control of high blood pressure and dyslipidemia were
enrolled during the 18-month follow-up period. The
baseline demographic, clinical, and disease
characteristics stratified according to ASCVD16 risk
group are presented in Table I. Of these, 307 patients
(57%) were male, and 368 patients (69%) met the
criteria for very high risk or high risk of ASCVD.
Although male sex was more prominent in the very-
high-risk group (64% male vs 36% female), female
sex was more prominent in the low-risk group (36%
male vs 64% female). The mean age of patients were
65.4 (11.6) years, which was significantly higher in
the very-high-risk group compared with the low-risk
group. The prevalence of coronary artery disease
(94%), peripheral artery disease (12%), and
cerebrovascular accident (5.5%) was distinctly higher
in patients at very high risk. We also noted that the
prevalence of low HDL-C (<40 mg/dL) was >30% in
patients at very high risk (32.1%) and patients at
high risk (35.0%), whereas the incidence was 17.4%
in the moderate-risk group. None of the patients with
low risk had low HDL-C levels.
The mean duration since the initial diagnosis of
hypertension was 9.8 (8.8) years; the duration wasVolume 42 Number 6
Table I. Demographic characteristics.
Characteristic Very High Risk High Risk Moderate Risk Low Risk Total
(n ¼ 308) (n ¼ 60) (n ¼ 121) (n ¼ 7) (N ¼ 536)
Male sex 197 (64%) 31 (52%) 62 (51%) 17 (36%) 307 (57%)
Age, mean (SD), y 67.8 (10.5) 66.6 (11.2) 62.6 (10.9) 55.0 (13.2) 65.4 (11.6)
Body mass index,
mean (SD), kg/m2
25.1 (3.2) 25.2 (3.1) 25.5 (3.4) 25.0 (4.0) 25.2 (3.3)
Hypertension 308 (100%) 60 (100%) 121 (100%) 47 (100%) 536 (100%)
Diabetes mellitus 104 (34%) 49 (82%) 0 0 153 (29%)
Low HDL (<40 mg/dL) 99 (32%) 21 (35%) 21 (17%) 0 141 (26%)
Cerebrovascular accident 17 (5.5%) 0 0 0 17 (3.2%)
Coronary artery disease 290 (94%) 0 0 0 290 (54%)
Peripheral artery disease 36 (12%) 0 0 0 36 (7%)
S.-J. Lee et al.longer as the ASVCD risk increased (11.6 [9.1] years
for very high risk, 9.4 [7.6] years for high risk, 7.6
[8.0] years for moderate risk, and 4.3 [6.1] years for
low risk). Prescription information regarding
antihypertensive agents including fimasartan is
presented in Table II. Seventy-three (23.7%) very
high risk patients were prescribed a combination
formulation containing fimasartan with rosuvastatin,
amlodipine, or diuretics. The mean duration of
dyslipidemia since the initial diagnosis was 4.8 (5.3)
years. Table III presents details on the prescribed
duration of the fimasartanerosuvastatin combination
formulation since receipt of informed consent. In
cases of single-agent rosuvastatin prescription, dosesTable II. Patients treated with antihypertensive agents co
Variable Very High Risk High Risk
(n ¼ 308) (n ¼ 60)
Single agent 237 (77.0%) 43 (71.7%)
Combined agent 73 (23.7%) 17 (28.3%)
Rosuvastatin 38 (52.1%) 8 (47.1%)
Amlodipine 16 (21.9%) 8 (47.1%)
Diuretics 19 (26.0%) 1 (5.9%)
Dosage
15 mg 9 (2.9%) 0
30 mg 107 (34.7%) 20 (33.3%)
60 mg 164 (53.2%) 32 (53.3%)
120 mg 28 (9.1%) 8 (13.3%)
June 2020of 5, 10, and 20 mg were prescribed for 54 patients,
299 patients, and 113 patients, respectively.
Concurrent Control Rate of Hypertension and
Dyslipidemia
Initially, we set the target blood pressure as 140/
90 mm Hg. The patients who satisfied both the target
blood pressure (<140/90 mm Hg) and the LDL-C
level in the protocol comprised 40.3% (216 of 536
patients; 95% CI, 36.2e44.5; P < 0.001). The rate
of satisfaction for both goals was lower as the
ASCVD risk increased (see Supplemental Table II in
the online version at doi:10.1016/j.clinthera.2020.03.
019). We also evaluated the rate of satisfaction forntaining fimasartan.
Moderate Risk Low Risk Total
(n ¼ 121) (n ¼ 47) (N ¼ 536)
83 (68.6%) 23 (49.0%) 384 (71.6%)
38 (31.4%) 24 (51.1%) 152 (28.4%)
25 (65.8%) 14 (58.3%) 85 (55.9%)
9 (23.7%) 9 (37.5%) 42 (27.6%)
4 (10.5%) 1 (4.2%) 25 (16.4%)
0 0 9 (1.7%)
52 (43.0%) 13 (27.7%) 192 (35.8%)
60 (49.6%) 30 (63.8%) 286 (53.4%)
9 (7.4%) 4 (8.5%) 49 (9.1%)
1061
Table III. Duration of treatment with a combination of fimasartan and rosuvastatin.
Variable Very High Risk High Risk Moderate Risk Low Risk Total
(n ¼ 38) (n ¼ 8) (n ¼ 25) (n ¼ 14) (N ¼ 85)
Treatment duration, d
Mean (SD) 162.5 (90.9) 167.0 (135.3) 124.6 (40.6) 116.6 (49.1) 144.2 (80.3)
Median 165.5 105.5 99 109.5 118
Minemax 57.0e554.0 85.0e486.0 85.0e204.0 29.0e234.0 29.0e554.0
Concomitant prescription
Ezetimibe 4 (10.5%) 2 (25.0%) 1 (4.0%) 1 (7.1%) 8 (9.4%)
Nicotinic acid 0 0 0 0 0
Omega-3 fatty acid 0 0 0 0 0
Minemax ¼ minimumemaximum.
Clinical Therapeuticsboth goals according to the revised diagnostic criteria
of hypertension (see Supplemental Table III in the
online version at doi:10.1016/j.clinthera.2020.03.
019), which also showed an inverse correlation
between concurrent control rate and ASCVD risk.
Indeed, concurrent control for hypertension and
dyslipidemia was 20.3% (95% CI, 17.2e24.0;
P ¼ 0.009) when applying the ACC/AHA
hypertension guidelines published in 2018 (<130/
80 mm Hg); that is, about one half of the patients
who met the protocol's target blood pressure (<140/
90 mm Hg) did not reach a revised, more strict target
blood pressure (<130/80 mm Hg) (Fig. 1).14 ForFigure 1. Percentage of patients reaching target blood p
1062control of blood pressure and LCL-C level, Cohen’s
kappa coefficient was 0.03, suggesting that there was
no significant correlation between the 2 parameters.
Control of Blood Pressure
The percentage of patients who reached the target
blood pressure (<140/90 mm Hg) of the original
protocol was 54.1% (290 of 536; 95% CI,
49.9e58.3; P ¼ 0.006). There was no significant
difference in blood pressure control between
subgroups of cardiovascular risk (P ¼ 0.9) (see
Supplemental Table IV in the online version at
doi:10.1016/j.clinthera.2020.03.019). Similarly, evenressure and LDL-C level. CV ¼ cardiovascular.
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were applied in 2017, there was no significant
difference in blood pressure control among the
subgroups of cardiovascular risk profiles. However,
when we applied the domestic guidelines for
hypertension, which suggests a target of <140/90 mm
Hg in the general population and a more strict target
(<130/80 mm Hg) in high- or very-high-risk groups,
there was a significant difference in blood pressure
control rate between the groups (Fig. 2). This
difference was derived from the lower blood pressure
control rate of the high-risk and very-high-risk
groups. Multivariate logistic regression analysis
revealed that blood pressure before the prescription
of fimasartan was significantly related to successful
blood pressure control (odds ratio, 0.99; 95% CI,
0.98e0.99; P ¼ 0.008).
Control of Dyslipidemia
The overall percentage of patients meeting the LDL-
C target level was 75.4%, which was significantly
different for the subgroups according to
cardiovascular risk (P < 0.0001). In the low-risk
group, the LDL-C level remained at the target level
for 100% of the patients, whereas the LDL-C
regulation rate decreased as the risk increased, which
was only 60.7% for the high-risk group (see
Supplemental Table V in the online version at doi:10.
1016/j.clinthera.2020.03.019). The control rate for
noneHDL-C was also similar to LDL-C controlFigure 2. Percentage of patients reaching target blood p
June 2020(Fig. 3). The percentage of patients who met the
noneHDL-C target level was 76.9% (95% CI,
73.1e80.2; P < 0.001), and the results were
significantly different among the subgroups according
to the cardiovascular risk (P < 0.001) (see
Supplemental Table VI in the online version at
doi:10.1016/j.clinthera.2020.03.019). Multivariate
logistic regression analysis revealed that high ASCVD
risk (compared with low risk; odds ratio, 0.1; 95%
CI, 0.02e0.19; P < 0.001) and diabetes mellitus
(odds ratio, 3.6; 95% CI, 2.0e6.4; P < 0.001) were
significantly related to a poor LDL-C control rate.DISCUSSION
Disease control rates for hypertension and
dyslipidemia were analyzed from 536 eligible patients
who were taking fimasartan and rosuvastatin for at
least 12 weeks among those who visited a general
hospital in the Republic of Korea ~1.5 years ago.
The percentage of patients who met both the target
blood pressure (<140/90 mm Hg) and LDL-C level
was 40.3% (95% CI, 36.2e44.5; P < 0.001). The
concurrent control rate was lower in groups at high
ASCVD risk; this group was older and had a higher
prevalence of male patients.
In a previous randomized controlled trial, the
concurrent control rate of hypertension and
dyslipidemia in patients simultaneously taking
fimasartan and rosuvastatin was 56.5%,17 reflecting
the difference in study design. An analysis for a large-ressure. CV ¼ cardiovascular.
1063
Figure 3. Percentage of patients reaching target LDL-C or non-HDL-C. CV ¼ cardiovascular.
Clinical Therapeuticsscale cohort database (National Health and Nutrition
Examination Survey 1999e2012) found that the
concurrent control rate of hypertension and
dyslipidemia was 25%, which was much lower than
our result.18 When target blood pressure was
adjusted to 130/80 mm Hg according to recent
guidelines,14 about one half of those who met the
conventional target blood pressure (<140/90 mm Hg)
did not meet the new criteria. However, this target
blood pressure is based on research data that
includes only about 2% of Asian subjects, and the
body mass index of subjects included in the study
was ~30 kg/m2, which is far from the national
average. Moreover, the study rarely included patients
with diabetes, stroke, or heart failure, limiting the
general application of the criteria to all the high-risk
patients with hypertension.
The Korean Society of Hypertension suggests 140/
90 mm Hg as a target blood pressure in the general
population and 130/80 mm Hg only in high-risk
patients, and 140/85 mm Hg in patients with
diabetes.15 When applying these criteria, the
concurrent control rate of hypertension and
dyslipidemia in the high-risk and very-high-risk
groups was 15.3% and 25.0%, respectively. This
suggests that patients with various cardiovascular
risk factors other than hypertension need more active
treatment and management. We note that the
prescription rate of the highest dose of fimasartan
(120 mg) was low in very-high-risk or high-risk1064patients, who require more stringent blood pressure
control, leading to the low control rate of
hypertension in these groups of patients. As a result,
regardless of the cardiovascular risk, the control rate
of blood pressure <140/90 mm Hg was similar.
However, LDL-C levels were almost completely
controlled in the low-risk and moderate-risk groups,
while the levels in the high-risk and very-high-risk
groups were 88.33% and 60.71%. Given the cross-
sectional design of this study, it is difficult to judge
from current data whether there is no sufficient
treatment available to achieve the LDL-C target level
in high-risk patients or the levels are still poor despite
optimal medical treatment, implying the patient
characteristics. There was no significant association
between blood pressure and lipid profile. Given that
drug compliance significantly affects clinical outcome,
the control rate of disease according to the drug
formula may be worth investigating in a separate
study with more sufficient sample size.
We also note that the achievement of risk factor
modification was much lower than expected in
patients with high or very-high-risk factors, who
require more stringent control of blood pressure and
cholesterol levels. Given that the most recent
guidelines suggest a lower cholesterol target (LDL-C
reduction 50% from baseline and LDL-C goal
<55 mg/dL) than the existing target cholesterol level
in high-risk patients,19 optimal medical therapy,
including an adequate dose antihypertensive orVolume 42 Number 6
S.-J. Lee et al.antidyslipidemic agent and a combination with
ezetimibe or proprotein convertase subtilisin/kexin
type 9 inhibitors, should be considered in patients
with multiple cardiovascular risk factors.
This study has several limitations. First, the study
patients were enrolled in a tertiary institute of >2000
beds, and thus it is difficult to assume that these
patients represent general characteristics of
hypertension and dyslipidemia. Second, if the LDL-C
value by direct measurement was missing, it was
replaced by using the Friedewald formula; it is
necessary to take this into account in the analysis of
results because the value of LDL-C calculated
indirectly tends to be lower than that by direct
measurement.20 Finally, other kinds of
antihypertensive agents included in combined agents
could have affected the control rate of hypertension,
and this factor should also be considered when
interpreting our results.
CONCLUSIONS
We conducted a cross-sectional study in 536 patients
with hypertension and dyslipidemia who were taking
fimasartan and rosuvastatin together for at least 12
weeks. When the target blood pressure was set at
140/90 mm Hg, the proportion of patients meeting
the target LDL-C level was 40.3% (95% CI,
36.2e44.5; P < 0.001), and the concurrent control
rate dropped by one half to 20.3% (95% CI,
17.2e24.0; P < 0.001) when the revised blood
pressure criteria targeting 130/80 mm Hg were
applied. This finding suggests that a more stringent
surveillance and treatment strategy is required for
patients with hypertension and other risk factors such
as dyslipidemia. There was no positive correlation
between the controlled rate of hypertension and
dyslipidemia.
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S.-J. Lee et al.SUPPLEMENTARY MATERIALSSupplementary Table 1. Target Lipid (LDL-C, non-HDL-C) Level
ASCVD risk LDL-C goal (md/dL) Non-HDL-C goal md/dL
Very high risk <70 <100
High risk <100 <130
Moderate risk <130 <160
Low risk <160 <190Supplementary Table 2. Number (%) of Subjects Reaching Target Blood Pressure (<140/90 mmHg) and LDL-C
(<70/100/130/160 mg/dL)
n (%) 95% C.I. Total P-value
Total 216 (40.3%) (36.2,44.5) 536 .
Very high risk 99 (32.1%) (27.2,37.6) 308 <0.0001y
High risk 25 (41.7%) (30.1,54.3) 60 .
Moderate risk 66 (54.6%) (45.7,63.1) 121 .
Low risk 26 (55.3%) (41.3,68.6) 47 .
y: Pearson's chi-square test, z: Fisher's exact test.Supplementary Table 3. Number (%) of Subjects Reaching Target Blood Pressure (<130/80 mmHg) and LDL-C
(<70/100/130/160 mg/dL)
n (%) 95% C.I. Total P-value
Total 109 (20.3%) (17.2,24.0) 536 .
Very high risk 46 (14.9%) (11.4,19.4) 308 0.001y
High risk 14 (23.3%) (14.4,35.4) 60 .
Moderate risk 39 (32.2%) (24.6,41.0) 121 .
Low risk 10 (21.3%) (12.0,34.9) 47 .
y: Pearson's chi-square test, z: Fisher's exact test.
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Supplementary Table 4. Number (%) of Subjects Reaching Target Blood Pressure (<140/90 mmHg)
n (%) 95% C.I. Total P-value
Total 290 (54.1%) (49.9,58.3) 536 .
Very high risk 166 (53.9%) (48.3,59.4) 308 0.9y
High risk 30 (50.0%) (37.7,62.3) 60 .
Moderate risk 68 (56.2%) (47.3,64.7) 121 .
Low risk 26 (55.3%) (41.3,68.6) 47 .
y: Pearson's chi-square test, z: Fisher's exact test.
Supplementary Table 5. Number (%) of Subjects Reaching Target LDL-C (<70/100/130/160 mg/dL)
n (%) 95% C.I. Total P-value
Total 404 (75.4%) (71.6,78.8) 536 .
Very high risk 187 (60.7%) (55.26,66.0) 308 <0.0001y
High risk 53 (88.3%) (77.8,94.2) 60 .
Moderate risk 117 (96.7%) (91.8,98.7) 121 .
Low risk 47 (100.0%) (92.4,100.0) 47 .
y: Pearson's chi-square test, z: Fisher's exact test.
Supplementary Table 6. Number (%) of Subjects Reaching Target non-HDL-C (<70/100/130/160 mg/dL)
n (%) 95% C.I. Total P-value
Total 412 (76.9%) (73.1,80.2) 536 .
Very high risk 200 (64.9%) (59.5,70.1) 308 <0.0001y
High risk 48 (80.0%) (68.2,88.2) 60 .
Moderate risk 117 (96.7%) (91.8,98.7) 121 .
Low risk 47 (100.0%) (92.4,100.0) 47 .
y: Pearson's chi-square test, z: Fisher's exact test.
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Supplementary Figure 1. Proportion of Subjects
According to a Cardiovascular Risk1e20 Group.
S.-J. Lee et al.
June 2020 1066.e3
